Pargolol

A comprehensive overview of the beta-blocker Pargolol

Introduction

Pargolol is a beta-blocker medication primarily used in the management of hypertension, angina pectoris, and certain types of arrhythmias. As a member of the beta-adrenergic blocking agents, Pargolol functions by inhibiting the action of epinephrine and norepinephrine on beta-adrenergic receptors, which are part of the sympathetic nervous system.

Pharmacology

Mechanism of Action

Pargolol works by blocking the beta-1 adrenergic receptors predominantly found in the heart and kidneys. This action results in a decrease in heart rate, myocardial contractility, and cardiac output, ultimately leading to a reduction in blood pressure. Additionally, Pargolol reduces the release of renin from the kidneys, contributing to its antihypertensive effects.

Pharmacokinetics

Pargolol is well absorbed from the gastrointestinal tract and undergoes significant first-pass metabolism in the liver. It has a bioavailability of approximately 50%. The drug is metabolized primarily by the cytochrome P450 enzyme system and is excreted in the urine. The half-life of Pargolol is about 6 to 8 hours, allowing for twice-daily dosing.

Clinical Uses

Hypertension

Pargolol is effective in lowering blood pressure in patients with essential hypertension. It is often used as part of a combination therapy with other antihypertensive agents such as diuretics or calcium channel blockers.

Angina Pectoris

In patients with angina, Pargolol reduces the frequency and severity of anginal attacks by decreasing myocardial oxygen demand.

Arrhythmias

Pargolol is used in the management of certain types of arrhythmias, including supraventricular tachycardia and atrial fibrillation. It helps to control the heart rate and restore normal rhythm.

Side Effects

Common side effects of Pargolol include fatigue, dizziness, bradycardia, and gastrointestinal disturbances. Less common but serious side effects can include bronchospasm, particularly in patients with asthma, and heart failure in susceptible individuals.

Contraindications

Pargolol is contraindicated in patients with severe bradycardia, second or third-degree heart block, and uncontrolled heart failure. Caution is advised in patients with diabetes mellitus and peripheral vascular disease.

Interactions

Pargolol may interact with other medications such as calcium channel blockers, antiarrhythmic agents, and nonsteroidal anti-inflammatory drugs (NSAIDs). These interactions can potentiate or diminish the effects of Pargolol.

Related pages

• Beta-blocker
• Hypertension
• Angina pectoris
• Arrhythmia

Chemical structure of Pargolol